Launch Date
08/09/2023 at 4:00 am EST
Credit Amount
0.75
Credit Expires
08/09/2024
Each day matters when it comes to slowing the progression of Alzheimer’s disease (AD), so it is imperative that health care professionals (HCPs) in this field are able to provide optimal care for patients with AD in a timely manner while applying the latest clinical trial data to practice, including the varied safety and efficacy data on new and emerging amyloid-targeting therapies (ATTs). ATTs have been shown to be promising in delaying disease progression in individuals with mild cognitive impairment or early dementia due to AD. To realize the full potential of ATTs, HCPs need education on clinical data of ATT agents in order to appropriately translate that information to improve diagnosis and management of AD.
In this CME Outfitters Snack, expert faculty will review data presented at the Alzheimer’s Association International Conference (AAIC) and will focus on established, new, and emerging ATTs as well as a case-based discussion on clinical impacts and applications to provide point-of-care tactics that will have a positive impact on patient outcomes.
Evaluate clinical practice implications of clinical trial data for established and emerging ATTs.
This activity is supported by an educational grant from Lilly.
Dementia specialists, neurologists, psychiatrists, neurology and psychiatry nurse practitioners (NPs), physician associates (PAs), and other clinicians caring for patients with AD in the United States and globally (with the exception of UK-based clinicians)
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Tangalos reports the following financial relationships:
Advisory Board: Acadia Pharmaceuticals Inc.; Biogen; and Eisai Inc.
Consultant: Cyclo Therapeutics, Inc. (DSMB); Genentech, Inc.; Prothena (DSMB); and Roche
Stock Shareholder (ownership interest): AbbVie Inc.; Johnson & Johnson; and Pfizer Inc.
Dr. Villain reports the following financial relationships:
Grants: Travel grant from GE Healthcare SAS; Merz-Pharma; and UCB Pharma GmbH
Other financial or material support: Unpaid local principal investigator or sub-investigator for Alector, Inc.; Biogen; Eisai Inc.; Eli Lilly and Company; Janssen Global Services, LLC/Johnson & Johnson; Novo Nordisk A/S; Roche; and UCB Pharma. Unpaid national coordinator for AB Science and ADvantage Therapeutics GmbH.
Unpaid lecturer in symposia organized by Eisai Inc. and the Servier Foundation.
Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
Call us at 877.CME.PROS (877.263.7767).
SN-205-08XX23-11